» Articles » PMID: 36196334

Role of Non-pharmacological Interventions and Weight Loss in the Management of Gastroesophageal Reflux Disease in Obese Individuals: A Systematic Review

Abstract

With the increasing prevalence of obesity, the worldwide risk of gastroesophageal reflux disease (GERD) has also increased. Abdominal obesity increases intragastric pressure, disturbing the integrity of the gastroesophageal junction, thus facilitating reflux. Other than obesity, some lifestyle factors also cause GERD, including smoking, consumption of alcohol and caffeine, late-night meals, and high fat intake. This review study aimed to assess the impact of weight loss and lifestyle modifications on GERD. In this systematic review, the databases used were PubMed, PubMed Central (PMC), Science Direct, and Google Scholar. Boolean system and Medical Subject Headings (MeSH) strategy were used to form suitable keywords. Patients from the pediatric and geriatric populations were excluded from the study and quality assessment was done using different assessment tools. A positive association between obesity and GERD was found. It was also found that the long-term use of proton pump inhibitors (PPIs) causes complications, so lifestyle interventions should be used more than PPIs for treating GERD, especially in obese patients. We concluded that weight loss could lead to the resolution of gastroesophageal reflux disease, and therefore, conservative measures, including dietary modifications such as reducing the consumption of alcohol, caffeine, and chocolate, behavioral changes such as smoking cessation and elevation of the head of the bed, and weight loss, should be used as first-line management for GERD. Although awareness has increased regarding the adverse effects of proton pump inhibitors, future studies are required to assess these negative effects.

Citing Articles

Akram's lifestyle: An effective remedy for the management of gastroesophageal reflux disease.

Khan S, Khan J, Akhter T, Khaar H, Yar T, Randhawa M J Family Community Med. 2025; 32(1):16-20.

PMID: 40018339 PMC: 11864353. DOI: 10.4103/jfcm.jfcm_302_24.


Non-Pharmacological approach for the management of gastroesophageal reflux disease.

Randhawa M, Khan S, Naseer A, Baqai M Pak J Med Sci. 2024; 40(3Part-II):549-551.

PMID: 38356802 PMC: 10862460. DOI: 10.12669/pjms.40.3.7291.


Gastro-Esophageal Reflux Disease and Paroxysmal Atrial Fibrillation Ablation.

Floria M, Iov D, Tanase D, Barboi O, Baroi G, Burlacu A Life (Basel). 2023; 13(5).

PMID: 37240752 PMC: 10220808. DOI: 10.3390/life13051107.

References
1.
Chang P, Friedenberg F . Obesity and GERD. Gastroenterol Clin North Am. 2014; 43(1):161-73. PMC: 3920303. DOI: 10.1016/j.gtc.2013.11.009. View

2.
Festi D, Scaioli E, Baldi F, Vestito A, Pasqui F, Di Biase A . Body weight, lifestyle, dietary habits and gastroesophageal reflux disease. World J Gastroenterol. 2009; 15(14):1690-701. PMC: 2668774. DOI: 10.3748/wjg.15.1690. View

3.
Ness-Jensen E, Hveem K, El-Serag H, Lagergren J . Lifestyle Intervention in Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol. 2015; 14(2):175-82.e1-3. PMC: 4636482. DOI: 10.1016/j.cgh.2015.04.176. View

4.
Aslam M, Slaughter J, Goutte M, Garrett C, Hagaman D, Vaezi M . Nonlinear relationship between body mass index and esophageal acid exposure in the extraesophageal manifestations of reflux. Clin Gastroenterol Hepatol. 2012; 10(8):874-8. DOI: 10.1016/j.cgh.2011.12.032. View

5.
Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. PMC: 8008539. DOI: 10.1186/s13643-021-01626-4. View